Pharmaceutical Compositions and Combinations
A compound of formula (I) combined with anticancer drugs increases cancer cell sensitivity, reduces side effects, and reverses immunosuppression, addressing the limitations of current cancer treatments by enhancing treatment efficacy and alleviating cachexia.
Patent Information
- Application Number
- JP2022543427
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-01-14
- Filing Date
- 2021-01-14
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-01-14
AI Technical Summary
Current cancer treatments, particularly chemotherapy, cause significant side effects and immunosuppression, leading to drug resistance and cachexia in cancer patients, with existing drugs affecting both cancer and normal cells and inducing immunosuppression in the tumor microenvironment.
The use of a compound of formula (I) or its pharmaceutically acceptable salts in combination with anticancer drugs, such as topoisomerase inhibitors and platinum-based drugs, to increase cancer cell sensitivity, reduce drug dosage, and reverse immunosuppression.
Enhances the sensitivity of cancer cells to anticancer drugs, reduces side effects, and alleviates cachexia by effectively lowering drug doses and reversing immunosuppression, thereby improving treatment outcomes.
Smart Images

Figure 0007579863000025 
Figure 0007579863000026 
Figure 0007579863000027
Abstract
Description
[Technical field]
[0001] The present invention relates to cancer treatment. More specifically, the present invention relates to the use of a compound of formula (I) and / or a pharma- ceutically acceptable salt of a compound of formula (I) in combination with an anti-cancer drug for cancer treatment, in particular to enhance the sensitivity of cancer cells to the anti-cancer drug, to reduce the side effects of the anti-cancer drug, to reverse the immunosuppression induced by the anti-cancer drug, and / or to reduce the symptoms of cachexia in subjects with cancer. JPEG0007579863000001.jpg32166 where A is a C1-C8 aliphatic hydrocarbyl with an optional carbonyl, X is H or OH, Y is O, and R1 is H or absent, except that when R1 is absent, Y and A combine to form a 5-membered ring. [Background technology]
[0002] In medicine, a tumor refers to an abnormal lesion of cells. Genetically, due to the action of various carcinogenic factors, cells in local tissues in the body can no longer control their normal growth, resulting in the abnormal growth of cells and forming a mass, called a "tumor." Cancer is also called a malignant tumor. Abnormally proliferating cancer cells not only form a mass, but also spread further and metastasize to other tissues and organs in the body. The growth and metastasis of cancer cells cause serious physiological dysfunction that is difficult to cure completely, so in recent years, cancer has become the leading cause of death worldwide.
[0003] Regarding the treatment of cancer, current common clinical therapies include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, etc., in which topoisomerase inhibitors, microtubule assembly inhibitors, platinum-based drugs, and / or antimetabolites are used in chemotherapy to kill rapidly proliferating cancer cells. However, most of the drugs used in chemotherapy also affect normal cells, affecting their proliferation, and cause serious side effects in cancer patients, such as nausea, vomiting, anorexia, hair loss, fatigue, bleeding, anemia, and leukopenia. Not only do they affect the quality of life of patients, but they can also cause cachexia, infections, or heart failure, thereby leading to the risk of death. Moreover, cancer cachexia is a comprehensive metabolic syndrome, which is associated with reduced caloric intake, increased static energy expenditure, and abnormal metabolism of proteins, fats, and carbohydrates. Cancer cachexia is characterized by weight loss, weakness, anorexia, fatigue, etc., and continued weight loss is inevitable even if patients increase their food intake and nutritional intake.
[0004] Some studies have shown that immune suppression of cancer cells is also associated with the development of cancer. Some cancer cells express their surface antigens (e.g., programmed death-ligands) to cause immune suppression of immune cells so that they are not activated. 1) It binds to immune cells via the aforementioned programmed death-ligand 1 (PD-L1 ) Any surface antigen on cancer cells is also called an "immune checkpoint antigen." Some studies have also shown that some anticancer drugs (such as gemcitabine) cause immunosuppression in the tumor microenvironment (TME), which allows cancer cells to resist the immune system. "Gemcitabine treatment promotes an immunosuppressive microenvironment in pancreatic tumors by supporting macrophage infiltration, growth, and polarization" (Scientific reports. 2018 August 10; 8 (1): 1-10.), etc., the contents of which are incorporated herein. .
[0005] Therefore, the industry is still devoted to researching medicines and therapies to treat cancer. If we can effectively increase the sensitivity of cancer cells to anticancer drugs or reduce the dosage of anticancer drugs, we can reduce the side effects of anticancer drugs, reduce the burden on patients, and alleviate the symptoms of cachexia. In addition, if we can reverse the immunosuppression caused by anticancer drugs, the therapeutic effect of anticancer drugs will be further enhanced, which will be beneficial for cancer treatment. Summary of the Invention
[0006] The inventors of the present invention have found that, compared with the use of an anticancer drug alone, the use of the compound of formula (I) of the present invention or a salt thereof in combination with an anticancer drug can enhance the sensitivity of cancer cells to the anticancer drug and effectively reduce the dosage of the anticancer drug, thereby achieving the objectives of reducing the side effects of the anticancer drug, reversing the immunosuppression induced by the anticancer drug, and alleviating the symptoms of cachexia in cancer patients.
[0007] It is therefore an object of the present invention to provide the use of an active ingredient in the manufacture of a pharmaceutical composition for use in combination with an anti-cancer agent to enhance the sensitivity of cancer cells to the anti-cancer agent, reduce the side effects of the anti-cancer agent, reverse the immunosuppression induced by the anti-cancer agent, and / or reduce the symptoms of cachexia in a subject with cancer, wherein the active ingredient is selected from the group consisting of a compound of formula (I), a pharma- ceutically acceptable salt of a compound of formula (I), and combinations thereof; JPEG0007579863000002.jpg32166, wherein A is a C1-C8 aliphatic hydrocarbyl optionally having a carbonyl, X is H or OH, Y is O, and R1 is H or absent, except that when R1 is absent, Y and A combine to form a 5-membered ring, and the anticancer agent is selected from the group consisting of a topoisomerase inhibitor, a microtubule assembly inhibitor, a platinum-based agent, an antimetabolite, and combinations thereof.
[0008] Another object of the present invention is to provide a use of a first active ingredient and a second active ingredient in the manufacture of a pharmaceutical composition for treating cancer, wherein the first active ingredient is selected from the group consisting of a compound of formula (I), a pharma- ceutically acceptable salt of a compound of formula (I), and combinations thereof; JPEG0007579863000003.jpg32166, wherein A is a C1-C8 aliphatic hydrocarbyl optionally having a carbonyl, X is H or OH, Y is O, R1 is H or absent, except that when R1 is absent, Y and A combine to form a 5-membered ring, and the second active ingredient is selected from the group consisting of a topoisomerase inhibitor, a microtubule assembly inhibitor, a platinum-based agent, an antimetabolite, and combinations thereof.
[0009] It is yet another object of the present invention to provide a combination comprising a first component and a second component, wherein the first component is selected from the group consisting of a compound of formula (I), a pharma- ceutically acceptable salt of a compound of formula (I), and combinations thereof; JPEG0007579863000004.jpg32166, where A is C1-C8 aliphatic hydrocarbyl with an optional carbonyl, X is H or OH, Y is O, R1 is H or absent, but when R1 is absent, Y and A are linked to form a 5-membered ring, and the second component is selected from the group consisting of topoisomerase inhibitors, microtubule assembly inhibitors, platinum-based drugs, antimetabolites, and combinations thereof. Preferably, the combination is in the form of a pharmaceutical composition or kit. According to an embodiment of the combination of the present invention, the combination is for use in the treatment of cancer.
[0010] Yet another object of the present invention is to provide a method for treating cancer, comprising administering to a subject in need thereof the above combination.
[0011] In said use, combination or method of the invention, with respect to the compound of formula (I), A is preferably a C1-C6 aliphatic hydrocarbyl, A is more preferably a C5 alkyl or alkenyl, and R1 is absent, or A is preferably a C1-C6 aliphatic hydrocarbyl with a carbonyl, A is more preferably a C5 alkyl or alkenyl with a carbonyl, and R1 is H.
[0012] In said uses, combinations or methods of the invention, when a pharma- ceutically acceptable salt of a compound of formula (I) is included, the pharma- ceutically acceptable salt is preferably at least one of the lithium, sodium, potassium, magnesium, calcium and zinc salts.
[0013] In said uses, combinations or methods of the invention, the anti-cancer agent, the second active ingredient and the second component are preferably independently selected from the group consisting of irinotecan, topotecan, etoposide, mitoxantrone, teniposide, azacitidine, 5-fluorouracil (5-FU), tegafur, TS-1, 6-mercaptopurine (6-MP), azathioprine, capecitabine, cladribine, clofarabine, cytosine arabinoside (Ara-C), decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine / tipiracil combination, cisplatin, oxaliplatin, paclitaxel, docetaxel and combinations thereof.
[0014] In the above uses, combinations or methods of the invention, the cancer is preferably at least one of colorectal cancer, colon cancer, lung cancer, pancreatic cancer, bladder cancer, bile duct cancer, rectal cancer, breast cancer, multiple myeloma, gynecological tumors, brain cancer, testicular cancer, leukemia, lymphoma, pleural mesothelioma, gastric cancer, liver cancer. [Brief description of the drawings]
[0015] [Figure 1]FIG. 1 shows images of Western blotting analysis of the expression of CD44ICD protein, PD-L1 protein, and GAPDH protein in Panc02 cells treated with different concentrations of (Z)-n-butylidenephthalide. [Diagram 2] FIG. 2 shows pancreatic tumor images (tumors are shown surrounded by dotted lines) of mice in each group, including the results of the "control" group, "LD" group (low dose), "HD" group (high dose), "Gem" group (gemcitabine), "LD+Gem" group, "TS-1" group, and "LD+TS-1" group, taken 15 days after orthotopically injecting Panc02 cells into the pancreas of the mice. [Diagram 3] FIG. 3 shows a histogram of tumor size analyzed from the dotted area in FIG. 2 (* indicates p-value<0.05 compared to the control group, ** indicates p-value<0.005 compared to the control group). [Figure 4] FIG. 4 shows the tumor size (expressed as Photon Flux) measured 1, 15, and 22 days after orthotopically injecting Panc02 cells into the pancreas of mice, including the results for the “Cisplatin” and “Z-BP+Cisplatin” groups. [Figure 5A-5D] 5A to 5D show curves of survival rates of mice bearing pancreatic cancer in response to different treatments. [Figure 6] Figure 6 shows the images of the expression of CD44 protein, CD44ICD protein, PD-1 protein, PD-L1 protein, p-Akt protein, Akt protein, and GAPDH protein in the pancreatic tumor tissue of mice with pancreatic cancer, visualized by different treatments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] Detailed techniques and some embodiments of the present invention are described below to allow those skilled in the art to understand the features of the present invention. However, the present invention can be embodied in various embodiments without departing from the spirit of the present invention, and should not be limited to the embodiments described herein.
[0017] Unless otherwise indicated herein, the terms "a," "an," "the," and the like when referenced in the specification (especially the claims) are intended to include both the singular and the plural. The term "subject" refers to human and non-human mammals (e.g., dogs, cats).
[0018] The definition of "response rate" refers to the proportion of patients who responded to treatment within any one period of observation, and the response level (the degree to which the tumor size is reduced) can be divided into complete response (tumor disappearance) and partial response (tumor size is reduced by at least 50%). For example, an anti-cancer drug with a "response rate of 40%" means that the drug can bring about an anti-cancer effect in 40% of patients treated with the drug, and the anti-cancer effect includes reducing the tumor size by at least 50% and even completely eliminating the tumor.
[0019] Clinical studies have shown that some patients experience low drug response rates and high chemotherapy-induced cytotoxicity / histotoxicity.
[0020] The inventors of the present invention have found that, compared with the use of an anticancer drug alone, the use of the compound of the present invention (i.e., the compound of formula (I)) or a salt thereof in combination with an anticancer drug can enhance the sensitivity of cancer cells to the anticancer drug and effectively reduce the dosage of the anticancer drug, thereby achieving the objectives of reducing the side effects of the anticancer drug, reversing the immunosuppression induced by the anticancer drug, and alleviating the symptoms of cachexia in cancer patients.
[0021] Thus, the present invention relates to the use of compounds of formula (I) and / or pharma- ceutically acceptable salts of compounds of formula (I) for treating cancer. JPEG0007579863000005.jpg32166 where A is a C1-C8 aliphatic hydrocarbyl with an optional carbonyl, X is H or OH, Y is O, and R1 is H or absent, except that when R1 is absent, Y and A combine to form a 5-membered ring.
[0022] Uses include: (i) Use of a compound of formula (I) and / or a pharma- ceutically acceptable salt of a compound of formula (I) in the manufacture of a pharmaceutical composition for use in combination with an anti-cancer agent to sensitize cancer cells to the anti-cancer agent, to reduce the side effects of the anti-cancer agent, to reverse immunosuppression induced by the anti-cancer agent, and / or to reduce symptoms of cachexia in a subject with cancer. (ii) Use of a compound of formula (I) and / or a pharma- ceutically acceptable salt of a compound of formula (I) as a first active ingredient and an anti-cancer agent as a second active ingredient in the manufacture of a pharmaceutical composition for treating cancer. (iii) A combination comprising a compound of formula (I) and / or a pharma- ceutically acceptable salt of a compound of formula (I) as a first component and an anticancer agent as a second component. thing (iv) the combination thing and administering to a subject in need thereof a method for treating cancer.
[0023] In the use of the present invention, for the compound of formula (I), A is preferably C1-C6 aliphatic hydrocarbyl (more preferably, A is C5 alkyl or alkenyl) and R1 is absent. Or, A is preferably C1-C6 aliphatic hydrocarbyl with carbonyl (more preferably, A is C5 alkyl or alkenyl with carbonyl) and R1 is H. For example, in some embodiments of the use of the present invention, the compound of formula (I) is (Z)-n-butylidenephthalide, (E)-n-butylidenephthalide, 2-pentanoylbenzoic acid or butylphthalide.
[0024] In the use of the present invention, the pharma- ceutically acceptable salt of the compound of formula (I) includes, for example, lithium salt, sodium salt, potassium salt, magnesium salt, calcium salt, and zinc salt.In some embodiments of the use of the present invention, the pharma- ceutically acceptable salt of the compound of formula (I) is a sodium salt, such as sodium 2-pentanoylbenzoate.
[0025] For use in the present invention, compounds of formula (I) and pharma- ceutically acceptable salts of compounds of formula (I) are either commercially available or can be prepared by synthetic methods known in the art.
[0026] Anti-cancer agents suitable for use in the present invention include, for example, topoisomerase inhibitors, microtubule assembly inhibitors, platinum-based agents, antimetabolites, and combinations thereof. Preferably, the anticancer agent is selected from the group consisting of irinotecan, topotecan, etoposide, mitoxantrone, teniposide, azacitidine, 5-fluorouracil (5-FU), tegafur, TS-1 (i.e., a combination drug containing a prodrug of 5-FU, tegafur), 6-mercaptopurine (6-MP), azathioprine (i.e., a prodrug of 6-MP), capecitabine, cladribine, clofarabine, cytosine arabinoside, decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine / tipiracil combination, cisplatin, oxaliplatin, paclitaxel, docetaxel, and combinations thereof. In some embodiments of the use of the present invention, the anti-cancer agent is one or more of irinotecan, 5-fluorouracil, TS-1, gemcitabine, cisplatin, oxaliplatin, and paclitaxel.
[0027] Combinations provided according to the present invention thing The combination according to the present invention may be a pharmaceutical composition or a kit. In an embodiment of the combination according to the present invention, the combination is used for the treatment of cancer. thingWhen it is a kit, (1) the compound of formula (I) and / or a pharma- ceutically acceptable salt as a first component, and (2) the anticancer drug as a second component, can be packaged and stored separately in different containers (e.g., plastic bags, plastic bottles, glass bottles, ampoules), and transported or sold alone or in combination as a set. In addition, the kit can further include an instruction manual that provides a procedure and program for a user to mix the components on-site for further processing and application.
[0028] In the context of use of the present invention, examples of cancer include colorectal cancer, colon cancer, lung cancer (such as non-small cell lung cancer), pancreatic cancer, bladder cancer, bile duct cancer, rectal cancer, breast cancer, multiple myeloma, gynecological tumors (such as cervical cancer, ovarian cancer, uterine cancer, vulvar cancer), brain cancer (such as glioblastoma), testicular cancer, leukemia (such as acute myeloid leukemia), lymphoma, pleural mesothelioma, gastric cancer, liver cancer, and the like.
[0029] The components of the pharmaceutical composition or kit provided according to the present invention can be administered systemically or locally and can be delivered by various drug delivery systems (DDS), and suitable drug delivery systems include oral drug delivery systems, transdermal drug delivery systems, injection drug delivery systems, inhalation drug delivery systems, and transmucosal drug delivery systems, etc. For example, in order to increase bioavailability, control drug release rate, precisely target lesions, and reduce side effects, the components of the pharmaceutical composition or kit provided according to the present invention can be delivered by, but are not limited to, liposomes, microcapsules, nanoparticles, or microneedles.
[0030] Depending on the desired purpose, the pharmaceutical composition or kit components according to the present invention can be provided in any suitable form without any particular limitation. For example, the pharmaceutical composition or kit components can be administered to a subject in need by oral administration, transdermal administration (such as a patch, ointment, etc.), corticospinal injection, intrathecal injection, intracerebral injection, intravenous injection (including drip and bolus injection), intramuscular injection, subcutaneous injection, intraarterial injection, intraperitoneal injection, subcutaneous implantation, interstitial injection implantation, airway (e.g., spray, nasal drops, etc.), or mucosal (e.g., oral dissolving tablets, etc.), but are not limited thereto. Depending on the form and purpose, a suitable carrier can be selected and used to provide the pharmaceutical composition or kit components, and carriers including excipients, diluents, auxiliary agents, stabilizers, absorption enhancers, disintegrants, hydrotropes, emulsifiers, antioxidants, adhesives, binders, tackifiers, dispersants, suspending agents, lubricants, moisture absorbents, etc. are known in the art and can be employed.
[0031] As a dosage form for oral administration, the pharmaceutical composition or kit components can be provided in a form suitable for oral administration, and liquid forms suitable for oral administration include syrups, oral liquids, suspensions, elixirs, etc., and solid forms suitable for oral administration include powders, granules, lozenges, sugar-coated tablets, enteric-coated tablets, chewable tablets, effervescent tablets, film-coated tablets, capsules, long-acting sustained-release tablets, etc. The pharmaceutical composition or kit components provided according to the present invention can include any pharma- ceutical acceptable carrier that does not adversely affect at least one desired effect of the anticancer agent and the compound of formula (I) and the pharma- ceutical acceptable salt of the compound of formula (I). For example, the pharma- ceutical acceptable carriers of the aforementioned liquid forms include, but are not limited to, water, saline, dextrose, glycerol, ethanol or its analogs, oils (e.g., olive oil, castor oil, cottonseed oil, peanut oil, corn oil, and germ oil), glycerin, polyethylene glycol, and combinations thereof. Additionally, the aforementioned solid form pharma- ceutically acceptable carriers include cellulose, starch, kaolinite, bentonite, sodium citrate, gelatin, agar, carboxymethylcellulose, gum arabic, seaweed gel, glyceryl monostearate, calcium stearate, and combinations thereof.
[0032] As a dosage form for transdermal administration, the pharmaceutical composition or kit components of the present invention may also contain a pharma- ceutically acceptable carrier that does not adversely affect at least one of the desired effects of the anticancer drug, the compound of formula (I) and the pharma- ceutically acceptable salt of the compound of formula (I), such as water, mineral oil, propylene glycol, polyethylene oxide, liquid petrolatum, sorbitan monostearate, polysorbate 60. The pharmaceutical composition or kit components may be provided in a form suitable for transdermal administration, such as, but not limited to, an emulsion, cream, oil, gel (such as hydrogel), paste (such as dispersion paste, ointment), lotion, spray, patch (microneedle patch), by any suitable method.
[0033] With respect to a form suitable for injection or infusion, the pharmaceutical composition or kit components may include one or more components such as an isotonic solution, a salt buffered saline (e.g., phosphate buffered saline or citrate buffered saline), a hydrotrope agent, an emulsifier, a 5% sugar solution, and other carriers to provide the pharmaceutical composition or kit components as an intravenous infusion, an emulsified intravenous infusion, an injectable powder, an injectable suspension, or an injectable powder suspension, etc. Alternatively, the pharmaceutical composition or kit components may be prepared as a pre-injectable solid, and the desired injection is provided by dissolving or emulsifying the pre-injectable solid in another solution or suspension prior to administration to a subject in need of the injection.
[0034] As a dosage form suitable for subcutaneous or interstitial implantation, the pharmaceutical composition or kit components provided by the present invention may further include one or more components such as excipients, stabilizers, buffers, other carriers, etc., to be prepared in the form of wafers, tablets, pills, capsules, etc., so that the pharmaceutical composition or kit components can be implanted into a subject, and at least one of the included anticancer drugs, the compound of formula (I) and the pharma- ceutically acceptable salts of the compound of formula (I) can be slowly and continuously released into the surrounding tissue to achieve a stable high-dose effect of killing cancer cells locally. For example, the pharmaceutical composition or kit components provided by the present invention may include a biocompatible polymer, and the pharmaceutical composition or kit components may be prepared in the form of wafers for subcutaneous implantation or interposition, but are not limited thereby. The biocompatible polymer may be commercially available or may be prepared by a synthesis method known in the field of the present invention. For example, the biocompatible polymer may be a polyanhydride, such as p(CPP-SA) copolymer prepared from bis(p-carboxylphenoxy)propane and sebacic acid.
[0035] For pharmaceutical compositions or kit components for airway administration, the pharmaceutical compositions or kit components can be optionally aerosolized by any suitable approach to facilitate the entry of the pharmaceutical compositions or kit components into the airway.For example, but not limited to, the pharmaceutical compositions or kit components can be administered through a nebulizer or a pressurized container (e.g., nasal spray).Alternatively, the pharmaceutical compositions or kit components can be prepared as nasal drops.
[0036] Regarding the pharmaceutical composition or kit component for transmucosal administration, the pharmaceutical composition or kit component provided by the present invention may contain one or more ingredients such as a penetrant, a surfactant, a viscosity adjusting agent, a pH adjusting agent, a preservative, a stabilizer, an osmotic pressure adjusting agent and other carriers, and the pharmaceutical composition or kit component may be provided in the form of eye drops, eye ointment, oral dissolving tablet, suppository, nasal spray, nasal spray, etc.
[0037] In some cases, the components of the pharmaceutical composition or kit provided according to the present invention may further comprise suitable amounts of additives such as toners and / or colorants to improve the palatability and visual appeal of the pharmaceutical composition or kit, and buffers, preservatives, antiseptics, antibacterial agents and / or antifungal agents to improve the stability and storage stability of the pharmaceutical composition or kit.
[0038] The pharmaceutical compositions or components of the kits provided according to the present invention may optionally contain one or more other active ingredients to further enhance the efficacy of the compositions or kits or to enhance the flexibility and adaptability of the application of the formulations provided, as long as the other active ingredients do not adversely affect the desired efficacy of the anticancer agent and / or the compound of formula (I), and the pharma- ceutically acceptable salts of the compound of formula (I), contained in the pharmaceutical compositions or kits of the present invention.
[0039] The pharmaceutical compositions provided in accordance with the present invention may contain at least one of the following inactive ingredients based on the total weight of the composition: 0.0001, 0.0002, 0.0003, 0.0004, 0.0005, 0.001, 0.0015, 0.002, 0.0025, 0.003, 0.0035, 0.004, 0.0045, 0.005, 0.0055, 0.006, 0.0065, 0.007, 0.0065, 0.007, 0.0075, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0. 7, 0.8, 0.9, 1, 5, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 wt% of at least one of the compounds of formula (I) and pharma- ceutically acceptable salts of the compounds of formula (I), and useful ranges can be selected from any two of these values, e.g., from about 0.0001 wt% to about 90 wt%, from about 0.001 wt% to about 25 wt%, from about 0.01 wt% to about 10 wt%, from about 0.01 wt% to about 5 wt%, from about 0.05 wt% to about 1 wt%, and from about 0.05 wt% to about 0.5 wt%.
[0040] Depending on the needs, age, weight, and health condition of the subject, as well as the purpose of application, the pharmaceutical composition or kit provided according to the present invention can be taken at various frequencies, such as once a day, multiple times a day, or once every few days. The amount of at least one of the anticancer agent and / or the compound of formula (I) and the pharma- ceutically acceptable salt of the compound of formula (I) in the pharmaceutical composition or kit provided according to the present invention can be adjusted, for example, to an amount to be taken daily or applied externally, depending on the needs of actual use.
[0041] In the methods provided by the present invention, the administration route, administration frequency, and dosage range of the pharmaceutical composition or kit are all in accordance with the above description.
[0042] The present invention will be described in more detail using the following specific examples. However, the following examples are provided only to illustrate the present invention, and the scope of the present invention is not limited thereby. The scope of the present invention is indicated by the claims. EXAMPLES
[0043] In the following preparation examples, the materials and equipment used are as follows: 1. Human pancreatic cancer cell lines: Mia-PaCa2 cells (purchased from Bioresource Collection and Research Center (website: https: / / www.bcrc.firdi.org.tw / wwwbcrc / index.do), BCRC60319), PANC-1 cells (purchased from Bioresource Collection and Research Center, BCRC60494), AsPC-1 cells (purchased from Bioresource Collection and Research Center, BCRC60494). 2. Mouse pancreatic cancer cell line: Panc02 cells (provided by Everfront Biotech Inc.). 3. Lung cancer cell line: A549 cells (purchased from Bioresource Collection and Research Center, BCRC60074). 4. Brain tumor cell line: DBTRG-05MG cells (purchased from the Biological Resource Collection and Research Center, BCRC60380). 5. Colorectal cancer cell line: HT-29 cells (purchased from Bioresource Collection and Research Center, BCRC67003). 6. Hepatoma cell line: HepG2 (purchased from Bioresource Collection and Research Center, BCRC60177). 7. Cell medium for Mia-PaCa2 cells: L-glutamine, sodium pyruvate (purchased from Thermo Fisher Scientific), 10% fetal calf serum (FCS; purchased from Gibco, product number: 1939760), 1% penicillin / streptomycin (P / S; purchased from Simply, product number: CC502-0100), and 2.3% horse serum (purchased from Gibco, product number: 16050122). 8. Cell medium for PANC-1 cells: DMEM-HG medium containing 10% fetal bovine serum and 1% penicillin / streptomycin. 9. Cell culture medium for AsPC-1 cells: RPMI1640 medium (purchased from HyClone) containing 10% fetal bovine serum, 1% penicillin / streptomycin, 10 mM HEPES (purchased from Biomedicals, product number: 194549), and 1 mM sodium pyruvate. 10. Cell culture medium for Panc02 cells: RPMI1640 medium containing 10% fetal bovine serum and 1% penicillin / streptomycin. 11. Cell culture medium for A549 cells: DMEM medium containing 10% fetal bovine serum. 12. Cell medium for DBTRG-05MG cells: RPMI1640 medium containing 10% fetal bovine serum and 1 mM sodium pyruvate. 13. Cell culture medium for HT-29 cells: RPMI1640 medium containing 10% fetal bovine serum. 14. HepG2 cell culture medium: DMEM medium containing 10% fetal bovine serum. 15. (Z)-n-Butylidenephthalide (Z-BP): Provided by Everfront Biotech Inc., purity 99.8%. 16. (E)-n-Butylidenephthalide (E-BP): Provided by Everfront Biotech Inc., purity 98.01%. 17. 2-Pentanoylbenzoic acid (BP-OH): Provided by Everfront Biotech Inc., purity 99.6%. 18. Sodium 2-pentanoylbenzoate (BPONa): Provided by Everfront Biotech Inc., purity 99.7%. 19. Butylphthalide: Provided by Everfront Biotech Inc., purity ≧97%. 20. Gemcitabine (GEM): Purchased from APEXBio, part number: A8437. 21. 5-Fluorouracil (5-FU): purchased from Sigma, part number: F6627. 22. Irinotecan (CPT-11): Purchased from Sigma. Part number: I1406. 23. Cisplatin (CDDP): Purchased from Sigma, part number: C2210000. 24. Oxaliplatin (OXA): Purchased from Sigma, part number: 61825-94-3. 25. Paclitaxel (PTX): Purchased from Sigma, part number: 33069-62-4. 26.TS-1: Provided by Everfront Biotech Inc. 27. MTT (Thiazolyl Blue Tetrazolium Bromide, 3-[4,5-Dimethylthiathiazol-2-yl]-2,4-diphenyl-tetrazolium bromide): purchased from ALFA Aesar™, product number: L11939-000000-16AF. 28. ELISA reader: purchased from Thermo Fisher Scientific, model number: 22662. 29. C57BL / 6J mice (body weight: 18–22 g): purchased from the National Laboratory Animal Center, Taipei, Taiwan. 30. Antibodies for Western blotting: anti-Akt antibody (purchased from Cell Signaling Technology, product number: #9272), anti-phospho-Akt (Ser473) antibody (purchased from Cell Signaling Technology, product number: #9271), anti-CD44 antibody (purchased from Abcam, product number: #ab24504), anti-PD-L1 antibody (purchased from Abcam, product number: #ab238697), anti-PD-1 antibody (purchased from BioLegend, product number: #367402), anti-GAPDH antibody (purchased from Genetex, product number: GTX100118).
[0044] Example 1: Effect of compounds of the present invention and different anticancer drugs on cancer cell killing In this example, the effect of the compounds of the present invention and different anticancer drugs on cancer cell killing was investigated by MTT (thiazolyl blue tetrazolium bromide, 3-[4,5-dimethylthiazol-2-yl]-2,4-diphenyl-tetrazolium bromide) cell viability assay.
[0045] 1-1. Effects of the compounds of the present invention and different anticancer drugs on the killing of pancreatic cancer cells Pancreatic cancer cell lines, PANC-1 cells, Mia-PaCa2 cells, AsPC-1 cells, and Panc02 cells, were cultured in 96-well plates (1 × 10 4 Cells / well, 96-well plates were placed in an incubator maintained at 37°C and 5% CO2 and cultured in each well for 24 hours. Then, each of the above cell lines was cultured in cell culture medium containing gemcitabine, cisplatin, 5-fluorouracil, irinotecan, oxaliplatin, paclitaxel, (Z)-n-butylidenephthalide, (E)-n-butylidenephthalide, 2-pentanoylbenzoic acid, sodium 2-pentanoylbenzoate, and butylphthalide for 24, 48, and 72 hours, respectively. Next, MTT was added independently to each well of the 96-well plate (the final concentration of MTT in the cell culture medium of each well was 0.5 mg / ml), and the 96-well plate was cultured in an incubator maintained at 37°C and 5% CO2 for 1.5 hours. After removing the cell culture medium, 100 μL of dimethyl sulfoxide was added, and the absorbance at 595 nm was measured with an ELISA reader to calculate the cell viability, and the 50% inhibitory concentration (IC50) of gemcitabine, cisplatin, 5-fluorouracil, irinotecan, oxaliplatin, paclitaxel, (Z)-n-butylidenephthalide, (E)-n-butylidenephthalide, 2-pentanoylbenzoic acid, sodium 2-pentanoylbenzoate, and butylphthalide was calculated for each of the pancreatic cancer cell lines. The results are shown in Table 1. JPEG0007579863000006.jpg105166
[0046] 1-2. Cancer cell killing effect of the compound of the present invention and 5-fluorouracil Lung cancer cell line (A549 cells), liver cancer cell line (HepG2 cells), colorectal cancer cell line (HT-29 cells), and brain cancer cell line (DBTRG-05MG cells) were cultured in 96-well plates (1 × 10 4 Cells / well, 96-well plate was placed in an incubator maintained at 37°C and 5% CO2, and cultured in each well for 24 hours. Then, each of the above cell lines was cultured in cell medium containing 5-fluorouracil, (Z)-n-butylidenephthalide, and 2-pentanoylbenzoic acid for 24, 48, and 72 hours. Next, MTT was added independently to each well of the 96-well plate (0.5 mg / ml), and the 96-well plate was cultured in an incubator maintained at 37°C and 5% CO2 for 1.5 hours. After removing the cell medium, 100 μL of dimethyl sulfoxide was added, and the absorbance at 595 nm was measured with an ELISA reader to calculate the cell viability, and the 50% inhibitory concentration (IC50) of 5-fluorouracil, (Z)-n-butylidenephthalide, and 2-pentanoylbenzoic acid in each of the pancreatic cancer cell lines was calculated. The results are shown in Table 2. JPEG0007579863000007.jpg54166
[0047] Example 2: Effect of combined use of the compound of the present invention and an anticancer drug
[0048] 2-1.(Z)-n-Butylidenephthalide and 5-Fluorouracil Pancreatic cancer cell lines (PANC-1 cells, Mia-PaCa2 cells, AsPC-1 cells), lung cancer cell line (A549 cells), liver cancer cell line (HepG2 cells), colon cancer cell line (HT-29 cells), and brain cancer cell line (DBTRG-05MG cells) were cultured in 96-well plates (1 × 10 4The cells / well, 96-well plate was placed in an incubator maintained at 37°C and 5% CO2, and cultured in each well for 24 hours. Then, both (Z)-n-butylidenephthalide and 5-fluorouracil were added simultaneously to the cell culture medium of each cell line. After placing the 96-well plate in an incubator maintained at 37°C and 5% CO2 for 1.5 hours, the cell culture medium was removed and 100 μL of dimethyl sulfoxide was added. Then, the cell viability was calculated by measuring the absorbance at 595 nm with an ELISA reader, and the 50% inhibitory concentration (IC50) of each cancer cell line for the above process was calculated. Finally, the combination index (CI) was calculated by formula A. The results are shown in Table 3.
[0049] JPEG0007579863000008.jpg15166
[0050] (D)1 and (D)2 independently represent the IC50 of drug 1 and drug 2 when used in combination, and (Dx)1 and (Dx)2 independently represent the IC50 of the above two drugs when used alone. When the combination index (CI) is less than 1, the use of the two drugs in combination is considered to have a synergistic effect.
[0051] JPEG0007579863000009.jpg74166
[0052] The results in Table 3 show that all CI values of (Z)-n-butylidenephthalide in combination with 5-fluorouracil to kill cancer cells are less than 1, and therefore can produce a synergistic effect.
[0053] 2-2.(Z)-n-Butylidenephthalide and other anticancer drugs According to the method of Example 2-1, pancreatic cancer cells are treated with (Z)-n-butylidenephthalide and other anticancer drugs in combination, and the experimental data is calculated to obtain the CI value of the above combination to kill pancreatic cancer cells.The results are shown in Table 4.
[0054] JPEG0007579863000010.jpg59166
[0055] The results in Table 4 indicate that (Z)-n-butylidenephthalide can be combined with other anticancer drugs to kill pancreatic cancer cells with a CI value of less than 1, thus resulting in a synergistic effect.
[0056] 2-3.(E)-n-Butylidenephthalide and anticancer drugs According to the method of Example 2-1, pancreatic cancer cells are treated with (E)-n-butylidenephthalide and anticancer drugs such as oxaliplatin, paclitaxel, gemcitabine, and 5-fluorouracil in combination, and the experimental data is calculated to obtain the CI value for killing pancreatic cancer cells when the above combination is used.The results are shown in Tables 5 to 7.
[0057] JPEG0007579863000011.jpg35166
[0058] JPEG0007579863000012.jpg28166
[0059] JPEG0007579863000013.jpg29166
[0060] The results in Tables 5 to 7 show that the CI value for killing pancreatic cancer cells by combining (E)-n-butylidenephthalide with an anticancer drug is less than 1, and therefore can produce a synergistic effect.
[0061] 2-4.2-Pentanoylbenzoic acid (BP-OH) and anticancer drugs According to the method of Example 2-1, pancreatic cancer cells (PANC-1, Mia-PaCa2, AsPC-1, Panc02), lung cancer cell lines (A549 cells), liver cancer cell lines (HepG2 cells), colorectal cancer cell lines (HT-29 cells), and brain cancer cell lines (DBTRG-05MG cells) were treated with 2-pentanoylbenzoic acid (BP-OH) in combination with anticancer drugs such as 5-fluorouracil, gemcitabine, oxaliplatin, and paclitaxel, and the experimental data was calculated to obtain the CI value for killing each cancer cell when used in the above combination. The results are shown in Tables 8 to 11.
[0062] JPEG0007579863000014.jpg82166
[0063] JPEG0007579863000015.jpg28166
[0064] JPEG0007579863000016.jpg28166
[0065] JPEG0007579863000017.jpg28166
[0066] The results in Tables 8 to 11 show that the CI value for killing cancer cells when 2-pentanoylbenzoic acid (BP-OH) is combined with an anticancer drug is less than 1, thus resulting in a synergistic effect.
[0067] 2-4. Sodium 2-pentanoylbenzoate (BPONa) and anticancer drugs According to the method of Example 2-1, pancreatic cancer cells were treated with 2-pentanoyl sodium benzoate (BPONa) in combination with anticancer drugs such as oxaliplatin, gemcitabine, 5-fluorouracil, and paclitaxel, and the experimental data was calculated to obtain the CI value for killing pancreatic cancer cells when the above combinations were used. The results are shown in Tables 12 to 14.
[0068] JPEG0007579863000018.jpg29166
[0069] JPEG0007579863000019.jpg28166
[0070] JPEG0007579863000020.jpg36166
[0071] The results in Tables 12 to 14 show that sodium 2-pentanoylbenzoate (BPONa) has a CI value of less than 1 for killing pancreatic cancer cells in combination with anticancer drugs, and therefore can produce a synergistic effect.
[0072] As can be seen from the results of these Examples, compared with the use of an anticancer drug alone, the use of the compound of formula (I) of the present invention or a salt thereof in combination with an anticancer drug can enhance the sensitivity of cancer cells to the anticancer drug and effectively reduce the dosage of the anticancer drug, thereby achieving the goals of reducing the side effects of the anticancer drug, reversing the immunosuppression induced by the anticancer drug, and alleviating the symptoms of cachexia in cancer patients.
[0073] Example 3: Effect of compounds of the present invention on downregulation of CD44 and PD-L1 expression It is known that programmed death-ligand 1 (PD-L1) on the surface of cancer cells binds to programmed death-1 (PD-1) on the surface of immune cells, killing the immune cells. In addition, CD44 and CD44ICD can enhance the expression of PD-L1, and downregulation of CD44 can inhibit the proliferation of cancer cells. CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancer (Cancer Research, February 1, 2020; 80(3):444-457), etc., the contents of which are fully incorporated herein by reference.
[0074] Panc02 cells (pancreatic cancer cell line) were cultured with 37.5 and 75 μg / ml (Z)-n-butylidenephthalide for 6 hours (a portion of cells was harvested after 3 hours of culture). Cellular proteins were then extracted, and the expression of CD44 intracellular domain (CD44ICD) protein and PD-L1 protein in cancer cells treated with (Z)-n-butylidenephthalide was measured by Western blotting. In addition, the expression of GAPDH protein was measured as an internal control. The results are shown in Figure 1.
[0075] From Figure 1, it can be seen that the expression of CD44ICD protein and PD-L1 protein in Panc02 cells both decreased with increasing concentration of (Z)-n-butylidenephthalide, and CD44ICD protein was completely inhibited at 6 hours. The above results indicate that (Z)-n-butylidenephthalide, in addition to inhibiting the proliferation of cancer cells, is more effective in inhibiting the CD44ICD protein of cancer cells, thereby achieving the effect of inhibiting the expression of immune checkpoint antigens. Therefore, it can block the binding between cancer cells and immune cells, and reverse the immune suppression induced by anticancer drugs.
[0076] Example 4: Use of compounds of the present invention in combination with anti-cancer agents to treat cancer 4-1. Establishment of animal models According to the requirements of the Institutional Animal Care and Use Committee (IACUC) of Donghua University, C57BL / 6J mice were kept at the Experimental Animal Center of Donghua University until they were 8–1 week old. Then, stably constructed Panc02 cells transfected with Luc-eGFP were orthotopically injected into the pancreas of the mice (1 × 10 6 The tumor size in the pancreas of the mice was then analyzed from the animal imaging results, and the mice were equally divided into nine groups according to tumor size and treated for 3 to 4 weeks under the following conditions:
[0077] (1) "Control (Ctl.)" group (n=5 mice): No treatment, only daily oral administration of a vehicle (containing neither the compound of the present invention nor other anticancer drugs). (2) “LD” group (5 mice): A low dose (12.5 mg / kg body weight) of (Z)-n-butylidenephthalide was orally administered daily. (3) “HD” group (5 mice): A high dose (25 mg / kg body weight) of (Z)-n-butylidenephthalide was orally administered daily. (4) “Gem” group (5 mice): 100 mg / kg body weight of gemcitabine (GEM) was injected intraperitoneally every 3 days. (5) “LD+Gem” group (5 mice): 12.5 mg / kg body weight of (Z)-n-butylidenephthalide was orally administered daily, and 50 mg / kg body weight of gemcitabine (GEM) was intraperitoneally injected every 3 days. (6) "TS-1" group (5 mice): 100 mg / kg body weight of TS-1 was orally administered daily for 5 days, and then oral administration of TS-1 was discontinued for 2 days. (7) “LD+TS-1” group (2 mice): 12.5 mg / kg body weight of (Z)-n-butylidenephthalide was orally administered every day, followed by 50 mg / kg body weight of TS-1 orally administered once a day, after which oral administration of TS-1 was discontinued for 2 days. (8) “Cisplatin” group (3 mice): 2.5 mg / kg body weight of cisplatin was injected intraperitoneally for 7 days. (9) “Z-BP + cisplatin” group (3 mice): 6.25 mg / kg body weight of (Z)-n-butylidenephthalide was orally administered daily, and 1.25 mg / kg body weight of cisplatin was intraperitoneally injected for 7 days.
[0078] 4-2. Observation of tumor size (T2 weighted MRI) The stably constructed Panc02 cells transfected with Luc-eGFP were orthotopically injected into the mice of each group of Example 4-1, and the growth of the pancreatic tumor in situ was measured, followed by drug treatment for 14 days (i.e., the 15th day). During this period, the pancreatic tumors of the mice of each group were analyzed, observed by T2-weighted MRI, and photographed for record. The results are shown in Figure 2. In addition, the size of the tumors (areas surrounded by dotted lines) of the mice of each group of Figure 2 was analyzed by Amido software. The results are shown in Figure 3.
[0079] Gemcitabine (GEM) and TS-1 are drugs for treating cancer in clinical practice. However, as shown in Figure 3, the tumor sizes of mice in the "Gem" and "TS-1" groups are larger than those of the untreated "control" group (also called the "Ctl." group). These results indicate that gemcitabine (GEM) and TS-1 induce immune suppression in the tumor microenvironment (TME), thereby causing drug resistance of cancer cells to the immune system.
[0080] Figure 3 also shows that the tumor size in the "LD+Gem" group is significantly smaller than that in the "Gem" group, and that the tumor size in the "LD+TS-1" group is significantly smaller than that in the "TS-1" group. From the above results, it can be seen that the combination of the compound of the present invention or a salt thereof with an anticancer drug can effectively reverse the immunosuppression caused by the anticancer drug, and more effectively inhibit tumor growth.
[0081] 4-3. Observation of tumor size (IVIS imaging system) Panc02 cells stably constructed and introduced with Luc-eGFP were orthotopically injected into the mice in each group of Example 4-1. On the 1st, 15th, and 22nd days, the tumor sizes of the mice in the "Cisplatin" group and the "Z-BP + Cisplatin" group were detected by an IVIS imaging system (detected by measuring the photon flux, unit: ph / s / cm 2 / sr). The results are shown in Figure 4.
[0082] From FIG. 4, it can be seen that the photon flux obtained from the "Z-BP+cisplatin" group on the 22nd day is significantly lower than that of the "cisplatin" group. In other words, the tumor size of the "Z-BP+cisplatin" group is significantly smaller than that of the "cisplatin" group. The above results also show that the compound of the present invention or its salt can be used in combination with an anticancer drug to effectively enhance the tumor growth suppression effect of the anticancer drug.
[0083] 4-4. Survival observation According to the method of Example 4-1, pancreatic cancer mice were generated, and the survival of the mice in each group was observed and recorded every day. The results are shown in Table 15 and Figures 5A to 5D. JPEG0007579863000021.jpg75166
[0084] From Table 15 and Figures 5A-5D, it can be seen that the survival time of mice in the "LD" group is longer than that of the "control" group (also called the "Ctl" group) and the "TS-1" group. In addition, the survival time of mice in the "LD" and "Gem" groups is 1.8 times that of the "control" group, and the survival time of mice in the "LD+Gem" group is 2.1 times that of the "control" group.
[0085] 4-5. Observation of protein expression After the observations in Examples 4-2 to 4-3, the mice in each group were sacrificed, and the pancreatic tumor tissues were collected to extract proteins. Then, the expression of CD44 protein, CD44ICD protein, PD-1 protein, PD-L1 protein, p-Akt protein, and Akt protein in the protein samples of each group was detected by Western blotting. Furthermore, the expression of GAPDH protein served as an internal control. The results are shown in FIG. 6.
[0086] From Figure 6, we can see that the expression of PD-1 and PD-L1 proteins in the "Gem" and "TS-1" groups of mice is higher than that in the untreated "control" group (also called "Ctl" group). The above results also indicate that gemcitabine (GEM) and TS-1 induce immunosuppression in the tumor microenvironment (TME), thereby causing drug resistance of cancer cells to the immune system.
[0087] FIG. 6 also shows that the expression of CD44 protein, CD44ICD protein, PD-1 protein, and PD-L1 protein in the "LD+Gem" group is significantly less than that in the "Gem" group, and the expression of CD44 protein, CD44ICD protein, PD-1 protein, and PD-L1 protein in the "LD+TS-1" group is significantly less than that in the "TS-1" group. The above results indicate that (Z)-n-butylidenephthalide is effective in inhibiting the expression of CD44 protein and CD44ICD protein in cancer cells, and further inhibiting the expression of immune checkpoint antigens such as PD-1 protein and PD-L1 protein. Therefore, (Z)-n-butylidenephthalide can block the binding of cancer cells and immune cells, thereby reversing the immunosuppression induced by anticancer drugs. The above results also indicate that the use of the compound of the present invention or its salt in combination with an anticancer drug can effectively reverse the immunosuppression induced by the anticancer drug, and may be beneficial in enhancing the therapeutic effect of the anticancer drug.
[0088] In addition, Figure 6 also shows that the expression of p-Akt protein (i.e., activated Akt protein) is decreased in response to the downregulation of PD-L1 protein. The above results can demonstrate that the PD-L1 signaling pathway is inhibited.
[0089] As seen in the animal experiments of this embodiment, by combining the compound of the present invention or a salt thereof with an anticancer drug, the sensitivity of cancer cells to the anticancer drug in the animal body can be increased and the dosage can be effectively reduced, thereby achieving the purpose of reducing the side effects of the anticancer drug, reversing the immunosuppression induced by the anticancer drug, and alleviating the symptoms of cachexia in cancer patients.
Claims
1. 1. A pharmaceutical composition for use in combination with an anti-cancer agent to enhance the sensitivity of cancer cells to said anti-cancer agent, reduce the side effects of said anti-cancer agent, reverse immune suppression induced by said anti-cancer agent, and / or reduce symptoms of cachexia in a subject with cancer, said pharmaceutical composition comprising an active ingredient and a pharma- ceutical acceptable carrier; The active ingredient is selected from the group consisting of a compound of formula (I), a pharma- ceutically acceptable salt of a compound of formula (I), and combinations thereof; where A is an optionally carbonyl-containing C1-C8 aliphatic hydrocarbyl; X is H or OH; Y is O; R 1 is H or does not exist, (i) R 1 is H, A is a C1-C8 aliphatic hydrocarbyl bearing a carbonyl, and said anticancer agent is selected from the group consisting of microtubule assembly inhibitors, platinum-based agents, antimetabolites, and combinations thereof; (ii) R 1 is absent, A is a C1-C8 aliphatic hydrocarbyl, Y and A combine to form a 5-membered ring, and the anticancer drug is selected from the group consisting of 5-fluorouracil (5-FU), irinotecan, gemcitabine, and combinations thereof; A pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt of the compound of formula (I) having a purity of 97% or more.
2. 10. The pharmaceutical composition of claim 1, used in combination with said anti-cancer agent to alleviate symptoms of cachexia in a subject with cancer.
3. A pharmaceutical composition for treating cancer, comprising a first active ingredient, a second active ingredient, and a pharma- ceutically acceptable carrier, wherein the first active ingredient is selected from the group consisting of a compound of formula (I), a pharma- ceutically acceptable salt of a compound of formula (I), and combinations thereof; where A is an optionally carbonyl-containing C1-C8 aliphatic hydrocarbyl; X is H or OH; Y is O; R 1 is H or does not exist, (i) R 1 is H, A is a C1-C8 aliphatic hydrocarbyl with a carbonyl, and said second active ingredient is selected from the group consisting of microtubule assembly inhibitors, platinum-based drugs, antimetabolites, and combinations thereof; (ii) R 1 is absent, A is a C1-C8 aliphatic hydrocarbyl, Y and A combine to form a 5-membered ring, and said second active ingredient is selected from the group consisting of 5-fluorouracil (5-FU), irinotecan, gemcitabine, and combinations thereof; A pharmaceutical composition comprising a compound of formula (I) or a pharma- ceutically acceptable salt of the compound of formula (I) having a purity of 97% or more.
4. A is a C1-C6 aliphatic hydrocarbyl; R 1 The pharmaceutical composition of claim 1 or 3, wherein:
5. A is a C1-C6 aliphatic hydrocarbyl having a carbonyl group; R 1 The pharmaceutical composition of claim 1 or 3, wherein is H.
6. The pharmaceutical composition of claim 4, wherein A is C5 alkyl or alkenyl.
7. The pharmaceutical composition of claim 5 , wherein A is a C5 alkyl or alkenyl having a carbonyl.
8. 6. The pharmaceutical composition of claim 5, wherein the pharma- ceutically acceptable salt is at least one of a lithium salt, a sodium salt, a potassium salt, a magnesium salt, a calcium salt, and a zinc salt.
9. R 1 2. The pharmaceutical composition of claim 1, wherein when is H, the anticancer drug is selected from the group consisting of azacitidine, 5-fluorouracil, tegafur, TS-1, 6-mercaptopurine, azathioprine, capecitabine, cladribine, clofarabine, cytosine arabinoside, decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine / tipiracil, cisplatin, oxaliplatin, paclitaxel, docetaxel, and combinations thereof.
10. R 1 4. The pharmaceutical composition of claim 3, wherein when is H, the second active ingredient is selected from the group consisting of azacitidine, 5-fluorouracil, tegafur, TS-1, 6-mercaptopurine, azathioprine, capecitabine, cladribine, clofarabine, cytosine arabinoside, decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine / tipiracil, cisplatin, oxaliplatin, paclitaxel, docetaxel, and combinations thereof.
11. 4. The pharmaceutical composition of claim 1 or 3, wherein the cancer is at least one of colorectal cancer, colon cancer, lung cancer, pancreatic cancer, bladder cancer, bile duct cancer, rectal cancer, breast cancer, multiple myeloma, gynecological tumors, brain cancer, testicular cancer, leukemia, lymphoma, pleural mesothelioma, gastric cancer, and liver cancer.
12. 4. The pharmaceutical composition of claim 1 or 3, wherein the cancer is at least one of colorectal cancer, colon cancer, lung cancer, pancreatic cancer, rectal cancer, brain cancer, and liver cancer.
13. A combination for treating cancer, comprising a first component, a second component, and a pharma- ceutically acceptable carrier, wherein the first component is selected from the group consisting of a compound of formula (I), a pharma- ceutically acceptable salt of a compound of formula (I), and combinations thereof; where A is an optionally carbonyl-containing C1-C8 aliphatic hydrocarbyl; X is H or OH; Y is O; R 1 is H or does not exist, (i) when R1 is H, A is a C1-C8 aliphatic hydrocarbyl with a carbonyl, and said second active ingredient is selected from the group consisting of microtubule assembly inhibitors, platinum-based agents, antimetabolites, and combinations thereof; (ii) R 1 is absent, A is a C1-C8 aliphatic hydrocarbyl, Y and A combine to form a 5-membered ring, and said second component is selected from the group consisting of 5-fluorouracil (5-FU), irinotecan, gemcitabine, and combinations thereof; A combination of a first component and a second component, characterized in that the purity of the compound of formula (I) or a pharma- ceutically acceptable salt of the compound of formula (I) is 97% or more.
14. A is a C1-C6 aliphatic hydrocarbyl; R 1 The combination according to claim 13, wherein:
15. A is a C1-C6 aliphatic hydrocarbyl having a carbonyl group; R 1 The combination of claim 13, wherein is H.
16. 15. The combination of claim 14, wherein A is a C5 alkyl or alkenyl.
17. 16. The combination of claim 15, wherein A is a C5 alkyl or alkenyl bearing a carbonyl.
18. 16. The combination of claim 15, wherein the pharma- ceutically acceptable salt is at least one of a lithium salt, a sodium salt, a potassium salt, a magnesium salt, a calcium salt, and a zinc salt.
19. R 1 14. The combination of claim 13, wherein when is H, the second component is selected from the group consisting of azacitidine, 5-fluorouracil, tegafur, TS-1, 6-mercaptopurine, azathioprine, capecitabine, cladribine, clofarabine, cytosine arabinoside, decitabine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, nelarabine, pemetrexed, pentostatin, pralatrexate, thioguanine, trifluridine / tipiracil, cisplatin, oxaliplatin, paclitaxel, docetaxel, and combinations thereof.
20. The combination according to any one of claims 13 to 19, wherein the combination is in the form of a pharmaceutical composition or a kit.
Citation Information
Patent Citations
Application of ligustilide as adjuvant drug of antitumor drugs
CN105748466A
Angelicae sinensis extract for cancer treatment
JP2006117663A
Novel 2-(α-n-pentanonyl)benzoate, its manufacturing method and uses
JP2007528878A
Use of phthalide derivatives
JP2009511436A
Pharmaceutical composition for treating encephaloma or pharmaceutical composition for reducing temozolomide resistance of encephaloma cell, and use thereof
JP2012144512A
